Search results
Displaying Results 2831-2840 of 16352 for "AVCJ webinar"
Japan's Kyulux raises $34m extended Series B
Japan-based Kyulux, which develops advanced lighting technology used in digital screens, has raised JPY3.6 billion ($34.3 million) from a group of VCs and strategic investors.
MBK exits China's Apex International
MBK Partners has agreed to sell Apex International, China’s second-largest air freight forwarder, to Swiss logistics giant Kuehne + Nagel.
CPE leads $300m round for China's ANE Logistics
ANE Logistics, one of China’s top three less-than-truckload (LTL) logistics players, has raised $300 million in funding led by CPE. Greater Bay Area Fund, Hong Kong-listed NWS Holdings, Liumai Capital, and Huagai Capital also took part.
B Capital launches SPAC
B Capital Group, a US-based venture capital firm with a presence in Singapore and a significant Asia portfolio, is looking to raise $300 million for a special purpose acquisition company (SPAC).
Temasek backs China industrial SaaS player
Temasek Holdings has led a RMB500 million ($77 million) round for Black Lake Technologies, a China-based software-as-a-service (SaaS) provider for manufacturers.
Korea's Tmon closes $276m pre-IPO round
PS Alliance, an investment unit of South Korean automotive and electronic components manufacturer Poongsung Group, has led a KRW305 billion ($276 million) commitment to local e-commerce platform Tmon.
CPE leads $123m round for China's Wangjiahuan
Shenzhen-based agricultural products distributor Wangjiahuan has raised RMB800 million ($123 million) in a Series B extension led by CPE.
India's Zolve raises $15m seed round
Accel and Lightspeed Venture Partners have led a $15 million seed round for Zolve, an India-based digital bank focused on cross-border services.
KKR loses managing director in Singapore
Terence Lee, a managing director at KKR who leads technology, media and telecom (TMT) and growth equity investments in Southeast Asia, has left the firm.
China's Regor Therapeutics raises $90m Series B
Lilly Asia Ventures (LAV) has led a $90 million Series B round for Regor Therapeutics, a Chinese drug developer specializing in bioinformatics.